Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 353

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 353
---
16,700. The Predecessor
made no contributions in the three- or nine-months ended September 30, 2023.

NOTE 12 – Subsequent Events

On October 1, 2024, the Company’s Board
of Directors granted Directors and Officers options to purchase up to 45,230 shares of common stock for $10.00 per share. The grants
have various vesting conditions, including time-based and performance-based terms. Additionally, on October 1, 2024, the exercise price
of all other outstanding options granted under the 2024 Plan was adjusted to $10.00 per share, with all other terms of the original grant
to remain without adjustment.

On October 23, 2024, the trading price for CERo
common stock closed under $0.10 (prior to the Reverse Stock Split) and was the tenth consecutive trading day to do so. On October 24,
2024, the Company received letter from the staff at The Nasdaq Global Market (“Nasdaq”) notifying the Company that, because
its Common Stock had a closing bid price of $0.10 or less for ten consecutive trading days, it was no longer eligible to rely upon the
180-day cure period that commenced when the Company received notice in July 2024 that the closing bid price was below $1.00 for ten consecutive
trading days and was scheduled to expire on January 15, 2025. In addition, on October 30, 2024, the Company received a letter from the
staff at Nasdaq notifying the Company that it had not regained compliance with the continued listing requirement to maintain a minimum
market value of $50,000,000 for its listed securities within the 180-day compliance period granted by Nasdaq in May 2024. Each such deficiency
results in the commencement of delisting proceedings. However, the Company has requested a hearing from Nasdaq and plans to submit a
plan to regain compliance with the listing requirements at such hearing.

On November 8, 2024, the Company consummated
a purchase agreement with Keystone pursuant to which we may sell and issue, and Keystone is obligated to purchase, up to $20.6 million
of shares of Common Stock, subject to certain market conditions. The price of the shares purchased by Keystone under the ELOC is 90%
of various volume-weighted average price (“VWAP”) and closing price-based formulae, and requires a waiver